
Acylcarnitine profiling in meningiomas with different NF2 mutation status


Joanna Bogusiewicz [1], Jacek Furtak [2,3], Marcin Birski [3], Krystyna Soszyńska [4], Anna Majdańska [4], Agata Ryfa [4], Marek Harat [2,3]* and Barbara Bojko [1]*

[1] Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
[2] Medical Faculty, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland
[3] Department of Neurosurgery, 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland
[4] Laboratory of Clinical Genetics and Molecular Pathology, Department of Medical Analytics, 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland
* Correspondence: harat@10wsk.mil.pl (M.H.), bbojko@cm.umk.pl (B.B.).


SUPPLEMENTARY MATERIALS




AC C2:0




AC C3:0




AC C4:0




AC C6:0




AC C8:0



AC C10:0








Figure S1. Receiver operating characteristic(ROC) curves for significantly altered acylcarnitines in NF2 mutated and NF2 wildtype meningiomas.
‘




Figure S2. Receiver operating characteristic(ROC) curve for all studied acylcarnitines in NF2 mutated and NF2 wildtype meningiomas.